Legend Biotech Corporation 9LB.F Stock
Legend Biotech Corporation Price Chart
Legend Biotech Corporation 9LB.F Financial and Trading Overview
| Legend Biotech Corporation stock price | 49.8 EUR |
| Previous Close | 65.5 EUR |
| Open | 64.5 EUR |
| Bid | 65 EUR x N/A |
| Ask | 65.5 EUR x N/A |
| Day's Range | 64.5 - 64.5 EUR |
| 52 Week Range | 38.8 - 67 EUR |
| Volume | 33 EUR |
| Avg. Volume | 5 EUR |
| Market Cap | 11.71B EUR |
| Beta (5Y Monthly) | -0.051387 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.74 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.75 EUR |
9LB.F Valuation Measures
| Enterprise Value | 9.88B EUR |
| Trailing P/E | N/A |
| Forward P/E | -52.86885 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 113.36717 |
| Price/Book (mrq) | 16.316721 |
| Enterprise Value/Revenue | 95.597 |
| Enterprise Value/EBITDA | -19.464 |
Trading Information
Legend Biotech Corporation Stock Price History
| Beta (5Y Monthly) | -0.051387 |
| 52-Week Change | 44.97% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 67 EUR |
| 52 Week Low | 38.8 EUR |
| 50-Day Moving Average | 56.94 EUR |
| 200-Day Moving Average | 48.61 EUR |
9LB.F Share Statistics
| Avg. Volume (3 month) | 5 EUR |
| Avg. Daily Volume (10-Days) | 3 EUR |
| Shares Outstanding | 180.35M |
| Float | 71.38M |
| Short Ratio | N/A |
| % Held by Insiders | 1.41% |
| % Held by Institutions | 39.26% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -500.39% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.71% |
| Return on Equity (ttm) | -96.39% |
Income Statement
| Revenue (ttm) | 103.3M EUR |
| Revenue Per Share (ttm) | 0.64 EUR |
| Quarterly Revenue Growth (yoy) | -12.099% |
| Gross Profit (ttm) | -284006000 EUR |
| EBITDA | -507374752 EUR |
| Net Income Avi to Common (ttm) | -526160992 EUR |
| Diluted EPS (ttm) | -3.07 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 850.12M EUR |
| Total Cash Per Share (mrq) | 5.14 EUR |
| Total Debt (mrq) | 314.76M EUR |
| Total Debt/Equity (mrq) | 48.19 EUR |
| Current Ratio (mrq) | 3.843 |
| Book Value Per Share (mrq) | 3.953 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -263647008 EUR |
| Levered Free Cash Flow (ttm) | -286797632 EUR |
Profile of Legend Biotech Corporation
| Country | Germany |
| State | NJ |
| City | Somerset |
| Address | 2101 Cottontail Lane |
| ZIP | 08873 |
| Phone | 732 317 5050 |
| Website | https://www.legendbiotech.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1390 |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Q&A For Legend Biotech Corporation Stock
What is a current 9LB.F stock price?
Legend Biotech Corporation 9LB.F stock price today per share is 49.8 EUR.
How to purchase Legend Biotech Corporation stock?
You can buy 9LB.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Legend Biotech Corporation?
The stock symbol or ticker of Legend Biotech Corporation is 9LB.F.
Which industry does the Legend Biotech Corporation company belong to?
The Legend Biotech Corporation industry is Biotechnology.
How many shares does Legend Biotech Corporation have in circulation?
The max supply of Legend Biotech Corporation shares is 181.91M.
What is Legend Biotech Corporation Price to Earnings Ratio (PE Ratio)?
Legend Biotech Corporation PE Ratio is now.
What was Legend Biotech Corporation earnings per share over the trailing 12 months (TTM)?
Legend Biotech Corporation EPS is -2.74 EUR over the trailing 12 months.
Which sector does the Legend Biotech Corporation company belong to?
The Legend Biotech Corporation sector is Healthcare.